Angela Kim
she/her/hers
About
Research
Publications
2026
NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition
Kim A, Bhardwaj P, Rehman S, Zhao S, Lucas K, Noronha K, Bhatt D, Friedman S, Morotti R, Sundaram R, Dela Cruz F, Feinberg T, Ramakrishnan S, Xue W, Barkauskas D, Hall D, Shern J, Sun W, Barr F, Yi J, Spurrier J, Yu A, Brenner C, Heer C, Heske C, Vasquez J. NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition. Molecular Cancer Therapeutics 2026, 10.1158/1535-7163.mct-25-0619. PMID: 42017774, PMCID: PMC13184901, DOI: 10.1158/1535-7163.mct-25-0619.Peer-Reviewed Original Researchpatient-derived xenograftsNAMPT inhibitorstherapeutic windowlack of predictive biomarkersbiomarker-driven strategiesprotein expressiontumor cell stainingChildren's Oncology GroupRMS cell linesorthotopic PDX modelsin vivo efficacypreclinical promisetumor regressionprimary tumorOncology GroupPDX modelspredictive biomarkerspediatric rhabdomyosarcomarhabdomyosarcoma modelmetabolic vulnerabilitiespromoter hypermethylationpromoter methylationrhabdomyosarcomaclinical trialsNA administration
2024
ASAP1 and ARF1 Regulate Myogenic Differentiation in Rhabdomyosarcoma by Modulating TAZ Activity
Hebron K, Perkins O, Kim A, Jian X, Girald-Berlingeri S, Lei H, Shern J, Conner E, Randazzo P, Yohe M. ASAP1 and ARF1 Regulate Myogenic Differentiation in Rhabdomyosarcoma by Modulating TAZ Activity. Molecular Cancer Research 2024, 23: 95-106. PMID: 39495123, PMCID: PMC11799837, DOI: 10.1158/1541-7786.mcr-24-0490.Peer-Reviewed Original Research
2023
Usability and Satisfaction Testing of Game-Based Learning Avatar-Navigated Mobile (GLAm), an App for Cervical Cancer Screening: Mixed Methods Study
. Usability and Satisfaction Testing of Game-Based Learning Avatar-Navigated Mobile (GLAm), an App for Cervical Cancer Screening: Mixed Methods Study. JMIR Formative Research 2023, 7: e45541. PMID: 37552527, PMCID: PMC10445170, DOI: 10.2196/45541.Peer-Reviewed Original Research
2022
The combination of trametinib and ganitumab is effective in RAS-mutated PAX-fusion negative rhabdomyosarcoma models
. The combination of trametinib and ganitumab is effective in RAS-mutated PAX-fusion negative rhabdomyosarcoma models. Clinical Cancer Research 2022, 29: 472-487. PMID: 36322002, PMCID: PMC9852065, DOI: 10.1158/1078-0432.ccr-22-1646.Peer-Reviewed Original ResearchEpithelial STAT6 O-GlcNAcylation drives a concerted anti-helminth alarmin response dependent on tuft cell hyperplasia and Gasdermin C
. Epithelial STAT6 O-GlcNAcylation drives a concerted anti-helminth alarmin response dependent on tuft cell hyperplasia and Gasdermin C. Immunity 2022, 55: 623-638.e5. PMID: 35385697, PMCID: PMC9109499, DOI: 10.1016/j.immuni.2022.03.009.Peer-Reviewed Original Research
News
News
- June 02, 2026
Ninth Annual YCC Trainee Research Colloquium Celebrates Outstanding Cancer Research
- May 01, 2025
New Research Presented from Yale Cancer Center at #AACR25
- April 21, 2025
Yale Cancer Center Research Breakthroughs Unveiled at AACR Annual Meeting
- November 13, 2024
Public School Students Explore Careers at Annual Yale Pathology Day
Get In Touch
Contacts
Email